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Inflammatory Bowel Diseases - ulcerative colitis and Crohn’s disease- are chronic gastrointestinal inflammatory diseases
of unknown etiology. Decreased oral intake, malabsorption, accelerated nutrient losses, increased requirements, and drug-
nutrient interactions cause nutritional and functional deficiencies that require proper correction by nutritional therapy. The
goals of the different forms of nutritional therapy are to correct nutritional disturbances and to modulate inflammatory
response, thus influencing disease activity. Total parenteral nutrition has been used to correct and to prevent nutritional
disturbances and to promote bowel rest during active disease, mainly in cases of digestive fistulae with high output. Its use
should be reserved for patients who cannot tolerate enteral nutrition. Enteral nutrition is effective in inducing clinical
remission in adults and promoting growth in children. Due to its low complication rate and lower costs, enteral nutrition
should be preferred over total parenteral nutrition whenever possible. Both present equal effectiveness in primary therapy
for remission of active Crohn’s disease. Nutritional intervention may improve outcome in certain individuals; however,
because of the costs and complications of such therapy, careful selection is warranted, especially in patients presumed to
need total parenteral nutrition. Recent research has focused on the use of nutrients as primary treatment agents.
Immunonutrition is an important therapeutic alternative in the management of inflammatory bowel diseases, modulating
the inflammation and changing the eicosanoid synthesis profile. However, beneficial reported effects have yet to be translated
into the clinical practice. The real efficacy of these and other nutrients (glutamine, short-chain fatty acids, antioxidants) still
need further evaluation through prospective and randomized trials.
DESCRIPTORS: Inflammatory bowel disease. Nutritional theray. Total parenteral nutrition. Enteral nutrition.
Inflammatory Bowel Diseases
(IBD) are often associated with signifi-
cant nutritional disturbances, such as
protein-calorie malnutrition and vita-
min and trace element deficits. Such
problems are aggravated by complica-
tions that occur during the evolution
of the disease, like bowel obstruction,
need for intestinal resections and dis-
ease activity16, 19. Thus, appropriate
nutritional management of IBD pa-
tients is an essential part of their man-
agement.
When analyzing nutrition and IBD,
three major aspects must be concerned:
the influence of nutritional compo-
nents in its pathogenesis, the impact
of IBD on nutritional status and the
potential role of nutritional therapy
(NT). Although important advances
have been recently achieved in the un-
derstanding of IBD pathogenesis, there
is still no consensus regarding the in-
dications and standards of NT for
these patients6, 26, 79.
This article reviews the importance
of nutritional deficits and their mecha-
nisms in IBD, discussing the role and
efficacy of enteral and parenteral nu-
tritional therapies.
Etiology and pathogenesis of IBD
IBD are characterized by chronic
and recurrent inflammation of the
bowel wall due to interaction of ge-
netic, environmental and immunologic
factors32, 72.
Initially one accepts that an unspe-
cific event (probably infection) trig-
gers a deregulated inflammatory and
immune response in a genetically sus-
ceptible individual. In a second stage
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this response is amplified through the
involvement of macrophages, lym-
phocytes and neutrophils17. Whether
this initial activation of immunologic
effectors is triggered by an intrinsic
(primarily deregulated immune sys-
tem) or extrinsic factor (an abnormal
breakdown in mucous barrier) is still
unknown52. Mucous barrier break-
down and the continuous exposure to
lumen dietary or bacterial antigens
perpetuate the inflammatory cascade.
Chronic inflammation results, then,
from the interaction between the
antigenic stimuli and individual ge-
netic and immunologic factors.
Polymorphonuclear cells, mono-
cytes and macrophages represent the
first line of intestinal defense. When
activated, phagocytes present antigens
to T cells, promoting the synthesis of
numerous mediators like cytokines,
arachidonic acid metabolites (eico-
sanoids), platelet activating factor,
bioactive amines, proteases, neuro-
peptides, nitric oxide and oxygen free
radicals72.
The amplification of inflammatory
response is more important in the
pathophysiology of intestinal tissue
lesions and histological alterations in
IBD than the initial event itself.
Moreover, effective therapeutic drugs
act by modulating the production of
inflammatory mediators; thus, even
though the initial event remains un-
known, it is believed that therapeutic
advances may occur by pharmacologi-
cal modulation of inflammatory media-
tors.
Beside genetic factors, geographic
variations in the incidence of IBD and
the increasing incidence of Crohn´s
Disease (CD) in the last decades sug-
gest that some environmental factors
might influence their pathogenesis.
Among those, dietary intake of sugars,
fibers, fruits, vegetables, fats and pro-
teins have been studied26. Even though
some potentially important correla-
tions have been found, the role of these
nutrients in IBD still needs more con-
clusive evidence16.
Nutritional deficits. Incidence, causes
and consequences
IBD symptoms include increased
bowel movements, blood loss, ab-
dominal pain, nausea, vomiting and
anorexia. Due to these alterations,
prevalence of IBD associated-malnutri-
tion is high, ranging from 23% in out-
patients to 85% in patients admitted
for clinical exacerbation25, 39. Malnutri-
tion is influenced by disease activity,
length and site of inflammation. Nu-
tritional deficits are more common in
small bowel CD than when inflamma-
tion is confined to the colon54.
Adequate nutritional care for IBD
patients requires identification and
correction of malnutrition-associated
factors, represented by either local and
systemic alterations or drug side ef-
fects (Table 1).
The reduction of dietary intake is
the main cause of malnutrition. It re-
sults from the fear of provoking ab-
dominal pain or diarrhea and imposed
dietary restrictions (“therapeutic fast-
ing”) during activity phases. Acute
anorexia is related to increased levels
of the cytokines IL-1 and TNF35.
Obstruction, fistulas or extensive
bowel inflammation also contribute to
decrease dietary intake, absorption and
body protein mass. Resection of the
terminal ileum can cause bile salt and
B12 deficiencies, leading to malab-
sorption of fats and fat-soluble vita-
mins. Bacterial overgrowth due to fis-
tulas, blind loop syndrome and bowel
stenosis might also impair nutrient ab-
sorption. Exsudative protein loss oc-
curs in areas of inflammation and mu-
cosa ulceration, being proportional to
disease activity.
Some nutritional deficits can also
be caused or amplified by the use of
drugs, such as corticosteroids (cal-
cium), sulfasalazine (folates), and
cholestiramine (vitamins). Sulfasala-
zine, 5-amyno salicylic acid and met-
ronidazole can cause nausea, vomit-
ing, taste derangement and dyspepsia.
Other nutritional deficits occur in
variable incidences, such as anemia
(54 to 80%), hypoalbuminemia (25 to
Table 1 - Factors involved in the development of malnutrition in Inflammatory
Bowel Diseases.
• Inadequate oral intake
abdominal pain, diarrhea, anorexia, nausea, vomiting, alimentary restrictions, side
effects of medications
• Malabsorption
extensive intestinal disease, surgical resections, biliary salt deficiency, bacterial
overgrowth, digestive fistulas, side effects of medications
• Increased intestinal loss
bleeding, digestive fistulas, protein- and biliary salt-losing enteropathy, loss of
electrolytes and minerals
• Increased calorie needs
growth period, acute inflammation, sepsis, fistulas, fever, disease activity
Table 2 - Factors determining tissue damage in Inflammatory Bowel Diseases.
• Reduction in splanchnic flow;
• Damage mediated by cytokines and oxygen free radicals;
• Lower availability of antioxidant nutrients (glutamine, glutathione, zinc, selenium,
vitamins A, C and E);
• Absence of enteral nutrition and/or insufficient supply of enterotrophic nutrients
(glutamine, short-chain fatty acids);
• Dimminished cellular capacity of using trophic nutrients or cellular resistence to growth
hormone (GH) action.
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80%), metals (iron, copper), trace ele-
ments (selenium, magnesium, zinc),
vitamins (A, B, D, E, K) and reduction
of enzymatic (superoxyde dismutase,
catalase, gluthatione peroxydase) and
non-enzymatic anti-oxidant activity
(vitamins C, E, b-carotene, glutha-
tione, taurine).
Anemia, a very frequent finding,
may be due to iron, folates and coba-
lamine (B12) deficiencies, chronic in-
flammation, intestinal resections, or
stool blood loss.
Hypoalbuminemia results from
anorexia, lower protein intake, re-
duced hepatic synthesis, intestinal loss
and catabolism (inflammation, fever or
corticosteroid administration). Greater
losses are due to disease activity rather
than its location 16. Therefore, serum
albumin levels are considered a better
marker for disease activity than nutri-
tional status, which can be better
analyzed through serum protein-bind-
ing retinol and pre-albumin26. Other
significant changes in body composi-
tion are related to disease activity, like
fat and water losses11, 49.
Nutritional deficits are associated
with adverse clinical outcome, affect-
ing cellular and humoral immunity,
linear body growth and sexual matu-
ration in children, fistula and wound
healing, nitrogen balance and bone
decalcification. Moreover, reduced
blood loss tolerance, greater postop-
erative morbidity rates and slower
functional recovery can occur32.
An interesting study by
Schneeweiss et al.73 showed that active
CD patients manifest alterations in
substrate oxidation similar to those
observed during prolonged fasting
(lower oxidation of proteins and glu-
cose and higher metabolism of fats),
without changes in energy require-
ments. These data demonstrate that
weight loss in these patients results
from anorexia, malabsorption and in-
testinal losses, rather than hyperme-
tabolism. As reintroduction of normal
dietary intake can reverse metabolic
changes, the importance of NT in this
population is well recognized.
There are differences in the devel-
opment and progression of nutritional
deficits in ulcerative colitis (UC) and
CD. Patients with CD develop malnu-
trition slowly, with frequent severe de-
ficiencies. On the other hand, patients
with UC usually preserve nutritional
status, but can develop severe defi-
ciencies very fast due to disease activ-
ity.
Thus, the most appropriate manage-
ment of IBD requires attention to nu-
tritional aspects from the initial diag-
nosis and the institution of necessary
therapeutic measures. For this purpose,
data from nutritional inquiry, physical
examination, anthropometrical meas-
ures and biochemical analyses are taken
into account together87. However, diffi-
culties in staging nutritional deficien-
cies in chronic disease do exist, because
it is usually difficult to differentiate nu-
tritional changes due to disease or re-
lated to malnutrition3.
NUTRITIONAL THERAPY IN IBD
General Measures
There does not exist a single uni-
formly effective dietary protocol for
patients with IBD3. The majority of
outpatients can usually adopt liberal
dietary intake of calories and proteins,
enough to keep and/or restore body
mass and to promote adequate devel-
opment of children and adolescents.
Even though many patients avoid a
series of foods for many reasons, they
should be encouraged to use almost
normal diets, provided that some re-
strictions might be necessary based on
individual intolerance32.
Thus, patients with lactose intoler-
ance benefit from its restriction, lower-
ing intestinal gas production and
diarrhea. Patients with intestinal steno-
sis must avoid food rich in fibers, such
as corn grains, seeds, fruits and vegeta-
bles. Patients with active ileal disease
or previously resected must adopt low
fat diets. The substitution of common
fat by medium chain tryglicerydes is
necessary in the presence of
steatorrhea. Some patients must also re-
strict oxalate ingestion to prevent uri-
nary stone formation. Attention must be
given to the detection of some micro-
nutrient deficiencies, such as iron, cal-
cium and cobalamine.
Most patients manifest iron-defi-
ciency hypochromic microcytic
anemia, treated with iron supplements.
Iron serum levels should guide provi-
sion of supplementary vitamin B12.
Refractory anemia can be managed
with oral iron and recombinant subcu-
taneous erythropoietin for 12 weeks75.
CD symptomatic patients should
receive multivitamin and mineral sup-
plements. Zinc deficiency due to pro-
longed diarrhea can be corrected with
a daily dosage of 20-50 mg. Risk of
osteoporosis (corticotherapy, post-
menopausal women, prolonged immo-
bilization, smokers, and positive fam-
ily history) is balanced with daily cal-
cium (1,000 mg) and vitamin D (400-
800 units)3.
Oral, enteral and parenteral nutri-
tional therapy might be necessary dur-
ing the different phases of IBD. When
calorie and protein intakes do not
match the needs for maintaining body
mass in adults and adequate growth in
children, some more effective nutri-
tional intervention must be tried, such
as the administration of liquid oral
supplements. When the risk of malnu-
trition persists, the benefits and risks
of enteral or parenteral nutrition must
be considered.
Currently, there is no solid evi-
dence to support caloric supplementa-
tion over the metabolic need predicted
by the Harris-Benedict formula; how-
ever, patients with less than 90% of
ideal body mass might need more calo-
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ries, mainly during active disease 39.
On the other hand, protein needs are
usually higher in IBD patients. There-
fore, adequate estimates of caloric (25-
35 kcal/kg/day for adults), protein
(1.0-1.5 g/kg/day for adults; 2.0 g/kg/
day for malnourished or septic pa-
tients), water and electrolyte needs are
essential and require attention to indi-
vidual needs13.
Endpoints, indications and selection
of route
The merits of anti-inflammatory
drugs in the treatment of IBD are well
established 82, 83. Drugs such as pred-
nisone, azathioprine, sulfasalazine and
mesalamine have achieved therapeutic
response levels around 60 to 80%, ver-
sus 30% with placebo47.
However, side effects with signifi-
cant impact on the patient’s quality of
life keeps alive the search for alterna-
tive therapeutic measures to control
malnutrition and inflammation. Thus,
the efficacy of NT must be analyzed
with those results in mind.
The main goals of NT are the main-
tenance and / or recovery of nutri-
tional status, remission of disease ac-
tivity, reduction of surgical indications
and postoperative complications6. De-
cisions regarding the appropriate use
of NT require an integrated evaluation
of patient’s nutritional status, severity
of disease, digestive tract function and
need for surgical treatment.
Generally, the enteral route is pre-
ferred since it is associated with fewer
complications and lower costs, thus
saving the parenteral route for patients
with contra-indications or intolerance
for enteral feeding. These cases in-
clude massive hemorrhage, intestinal
perforation or obstruction, toxic mega-
colon, and some cases of extreme short
bowel syndrome.
Specialized NT is indicated in
acute, severe and recurrent exacerba-
tion, preoperative preparation of mal-
nourished patients, digestive tract fis-
tulas, short bowel syndrome (anatomic
or functional), and growth retard. Usu-
ally, many of those indications are
based on clinical expertise rather than
on clinical trials results. The rationale
of these indications lies on the fact that
malnourished patients have wound
healing and immunologic impairment.
Reviews of uncontrolled studies in
malnourished patients reveal that
preoperative total parenteral nutrition
(TPN) reduces complications and the
extent of intestinal resection, even
though increasing hospital admission
lengths3.
With these data in mind, severity of
disease and the period of inadequate
nutritional intake have been often used
as criteria for NT indication, rather than
diagnosis of IBD itself. During a 5-7
days period of inadequate nutritional
intake, well-nourished patients have
only moderate metabolic stress with
minimal functional consequences.
However, greater metabolic stress or
malnutrition shorten this period and
force earlier institution of NT49.
IBD during childhood or early
adolescence has a great impact on nu-
tritional status and growth. The preva-
lence of linear growth retard in large
series varies from 36 to 88%33. In these
patients, NT is indicated as an adjunct
to correct and to prevent malnutrition,
promoting growth and as primary
therapy for active inflammation, espe-
cially in CD21.
Growth retard has multifatorial
etiology, and it is mainly related to in-
adequate food ingestion and anorectic
effects due to increased expression of
cytokines (TNF-a). Serum changes in
growth hormone levels have also been
implicated33,35.
The response to enteral nutrition
(EN) in children is similar to that ob-
served in adults, and male patients are
more vulnerable to growth impairment
since it occurs in a later period. In
pediatric patients, night time infusion
of dietary solutions is a common prac-
tice, avoiding major interference with
everyday activities32.
The use of EN in children must take
into account their acceptance and tol-
erance as many products have unpleas-
ant tastes and are delivered through
nasogastric feeding tubes. This problem
is partially controlled by using poly-
meric rather than elemental diets, with-
out reduction in treatment efficacy.
The benefits of bowel rest, TPN
and elemental diets in patients with re-
fractory CD have been known for more
than 25 years, including better nutri-
tional status, symptomatic relief and
even temporarily complete clinical re-
mission16. The use of NT for control-
ling symptoms and signs of a disease
is called primary nutritional therapy.
Both CD and UC exhibit different
responses to enteral and parenteral nu-
tritional support. Recently, excellent
literature reviews50,66,81 and meta-analy-
ses22,34 concerning primary NT of IBD
have been published.
Total Parenteral Nutrition (TPN)
TPN aims are preoperative bowel
rest, fulfilling postoperative nutritional
requirements and correcting malnutri-
tion. It can also be used as primary
therapy for active and severe IBD39.
Bowel rest is believed to improve con-
trol of intestinal inflammation reduc-
ing the presence of antigens and bac-
terial growth in the lumen, reducing
peristaltic movements and digestive
tract secretion, leading to relief of
symptoms77.
In other cases, TPN can be used as
a complement to poorly tolerated or
quantitatively insufficient oral or en-
teral nutrition to maintain patient’s
nutritional status or to correct malnu-
trition60.
Indication of primary TPN and
bowel rest for acute active IBD is still
controversial, since total bowel rest is
not essential for disease remission31.
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Furthermore, it is well known that ex-
clusive TPN leads to profound
morpho-functional changes (mucous
atrophy, bacterial translocation, en-
zyme and hormone alterations, intra-
hepatic cholestase, and macrophage
dysfunction). For that reason, it has
gradually lost space in face of the ben-
efits associated to nutrient provision
directly to the mucosa18. Moreover, the
use of TPN adds significant costs and
length to hospital admissions, espe-
cially when septic, metabolic or ve-
nous access complications occur20.
Malnutrition related complications
occur in a significant number of IBD
patients after surgical treatment38. Re-
duction of these complications with at
least 5 days of preoperative TPN is
well observed in patients with severe
malnutrition, presenting low serum al-
bumin (< 3.5 g/dL) and transferin (<
150 mg/dL) levels70. In these situation,
TPN provides nutritional requirements,
preserves lean body mass and func-
tional capacity and prevents protein
loss in acute disease course4,11.
In primary NT the association of
bowel rest and TPN reduces mucosal
inflammation and disease activity.
During acute toxic colitis, TPN main-
tains protein reserves, provides calo-
ries and reduces surgical complica-
tions15. However, the likelihood of to-
tal remission with TPN decreases with
more severe acute disease course, even
when it is associated with optimal
clinical treatment59. TPN also shows
fewer benefits during acute courses of
UC than CD77.
Classical indications of TPN in CD
patients are remission of acute disease,
control of abdominal pain and
suboclusive episodes76. Therefore,
TPN has a potential primary therapeu-
tic role in acute CD, with favorable
clinical response in cases of ileitis19,77.
In cases of intestinal obstruction, TPN
is essential in malnourished patients
and when one previews a fasting pe-
riod greater than 5 days.
TPN can become a valuable alter-
native for obtaining symptom remission
and postponing surgical indications,
especially in refractory corticoid
therapy53. However, even though TPN
is effective in refractory CD with an av-
erage hospital remission of 64% (40 to
80%) in the short term, reviews on the
subject showed less encouraging long
term remission (less than 50%)16,39,79.
The observed numeric variations
occur due to different populations,
length of TPN, definitions for remis-
sion and recurrence and simultaneous
use of medications. Han et al.39 pro-
spectively analysed 170 patients with
CD, showing an 81% initial clinical
remission that was reduced to 23% af-
ter 12 to 24-month follow-up. Fisher23
reported greater remission rate (75%)
in patients with small bowel than in
those with colonic CD (50%). How-
ever, this better response was not uni-
formly observed in other series59,76.
In a series of 100 patients with re-
fractory CD with optimal clinical treat-
ment, the addition of TPN was effec-
tive for clinical remission in 75%, re-
lieved obstructive symptoms in 75%,
decreased the inflammatory mass in
82% and achieved fistula healing in
62%65. Significant reduction in dis-
ease activity index, weight gain and
elevation of serum albumin levels
were also achieved in these patients.
Fistulas due to CD are common,
because of the characteristic transmu-
ral inflammation. Complicated or
symptomatic fistulas usually require
surgical treatment. Numerous reports
about the effects of TPN in intestinal
fistulas reveal initial closure rates of
44%39. Indeed, low output cutaneous
fistulas may have some benefit from
TPN, reducing morbidity and improv-
ing local conditions for surgical treat-
ment3. However, there is still a lack of
controlled prospective studies on this
matter.
Other possible indication for TPN
is perianal CD, which treatment is usu-
ally conservative due to frequent recur-
rences and possible involvement of
sphincter muscles. Early NT in mal-
nourished patients can promote bowel
rest and improve local wound heal-
ing83.
Long-term TPN has an important
role in maintaining nutritional status
and improving quality of life in short
bowel syndrome or chronic
suboclusive disease. Home TPN pro-
duces dramatic results in CD patients
with less than 100 cm of jejunum or
less than 50 cm of jejunum with intact
colon, but also in cases of congenital
and ischemic anomalies, motility dis-
orders, radiation enteritis and trauma44.
In patients with UC, TPN is not
considered an effective primary treat-
ment. Prospective and retrospective
studies showed remission rates lower
than 40% (initial) and 10 to 30% (late),
results not different than those ob-
tained in control groups39.
The presented data indicates that
TPN should be offered to IBD patients
in need for NT who do not tolerate the
enteral route, especially during acute
and severe disease courses. The avail-
able experience supports the use of
TPN for at least 5 days to correct se-
vere preoperative malnutrition in elec-
tive surgical situations or at least 1-3
days in cases of intense disease activ-
ity4.
TPN is also effective as primary
treatment in refractory CD, even
though a higher late recurrence rate is
observed when compared to surgical
treatment. On the other hand, primary
TPN is not effective in the treatment
of complex CD fistulas and UC.
Finally, long-term home TPN plays
a major role in improving the quality
of life of patients with CD and severe
short bowel syndrome.
Enteral Nutrition (EN)
EN comprises direct delivery of
nutrients to the gastrointestinal tract
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through different liquid formulas ad-
ministered by naso/oral or enteral
tubes, percutaneous feeding tubes or
gastrostomies / jeunostomies. In IBD,
EN is provided to correct nutritional
deficits or serve as primary therapy for
clinically active disease.
Polymeric diets are most often pre-
scribed, mainly in patients with ad-
equate gastrointestinal function. El-
emental diets contain nutrients in its
simple form, being historically indi-
cated for patients with malabsorption.
Intolerance to polymeric diets and
short bowel syndrome are the main in-
dications to semi-elemental
(olygomeric) and elemental formulas.
Recently, the recognition of TPN
potential complications and the ben-
efits of direct nutrient delivery to the
gastrointestinal lumen have reaffirmed
the importance of EN in several condi-
tions. Other advantages include lower
costs, easy administration and lower
complication rates. Even though fre-
quent, complications like diarrhea,
flatulence, colicky pain, gastro-
esophageal reflux and aspiration are
less severe than those caused by TPN.
Despite the benefits of EN in the
treatment of CD, the simplicity of drug
treatment makes that the obvious
choice. The palatability of enteral di-
ets, monotony of use of liquid formu-
las and the frequent need for tube feed-
ing can make EN very little attractive.
On the other hand, EN does not cause
side effects such as osteonecrosis, mus-
cle mass loss and psychological distur-
bances, as observed with steroids.
If intestinal obstruction is not
present, there is no contra-indication
to EN15. Furthermore, the similar early
remission rates of enteral diets and
TPN in CD suggest that bowel rest
provided by TPN does not influence
the efficacy of treatment51.
Despite its therapeutic effects have
been known for more than two decades,
the use of EN still raises controversy15.
The potential role of EN in the primary
treatment of active CD was discovered
by chance, when patients treated with
elemental diets preoperatively pre-
served nutritional conditions and also
had inflammatory activity control-
led86.
Elemental diets were introduced
initially as primary treatment for active
CD due to its low allergenic capacity,
providing lower antigenic (since they
don’t have integral proteins or peptides)
and inflammatory stimulation. As ab-
sorbed by the proximal jejunum, el-
emental diets provide nutrients and
trophic stimuli for this segment, keep-
ing the distal small bowel and colon
(more common sites of CD activity) at
relative rest. Elemental and olygomeric
diets also reduce the bacterial load, de-
creasing intestinal permeability.
Elemental and polymeric diets can
induce active CD remission as effec-
tively as corticosteroids15. However,
there aren’t enough data to support the
substitution of drug therapy by EN50.
Beside other mechanisms, EN decreases
CD activity by decreasing the synthe-
sis of inflammatory mediators and by
providing specific nutrients16,32.
Comparative studies have reported
that steroids and sulfasalazine therapy
are superior when compared to el-
emental diets55,57. Meta- analyses of
randomized controlled trials also favor
drug therapy over EN regarding remis-
sion of active CD in adults22,34. Moreo-
ver, results about late remission rates
reached the same conclusion 29 , al-
though the use of exclusion diets may
improve late remission rates68.
Comparative studies regarding the
efficacy of different EN formulations
in active CD have questioned the role
of elemental formulas. Rigaud67
showed similar results with elemental
and polymeric diets used as primary
therapy for steroid-unresponsive CD.
This fact suggests that some patients
may benefit from NT after drug treat-
ment failure15 In a prospective study
comparing TPN, oral diets plus TPN
and elemental diets, Greenberg et al.31
observed no significant differences on
remission, concluding that the benefits
of these regimens were due to nutri-
tional improvement. Recent literature
reviews22,50 and meta- analyses of con-
trolled randomized trials34 have not
shown any significant difference be-
tween elemental, oligomeric and poly-
meric diets concerning initial or late
remission of active CD, even though
elemental diets are related to earlier re-
mission.
Although differences in nitrogen
sources of enteral feeds are not relevant
to their therapeutic efficacy, polymeric
diets should be preferentially used in
treatment of acute CD, once it offers
lower costs, better patient tolerance,
and the possibility of immunological
action of its contents85. Furthermore,
the lipidic composition of polymeric
diets includes oleic acid, a mono-
unsaturated fatty acid that is not a pre-
cursor of eicosanoids or arachidonic
acid. This advantage is not found in
regular oral diets, rich in linoleic acid.
Concerning clinical remission,
drug treatment is more efficient than
EN therapy; on the other hand, late re-
mission rates are significantly higher
than those observed using placebo (20
to 40%) in mild or moderate CD3,33.
These results suggest that EN, when
tolerated by the patient, is beneficial.
The use of EN in active CD during
3 to 6 weeks may decrease disease ac-
tivity and induce early remission (be-
fore 3 months) in 29 to 88% (average
68%) of patients16,22,30. Further studies
showed that TPN and elemental diets
have similar early remission rates,
whereas TPN and polymeric diets have
similar effect on late remission; remis-
sion rates after one year of EN treat-
ment varied from 0 to 56%, and from
17 to 50% for TPN19.
The use of different formulations
and patient selection biases may be
the cause of different success rates us-
ing EN. A negative correlation be-
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tween remission rates and long-chain
triglyceride intake was observed in a
meta- analysis of 15 randomized con-
trolled series61. EN efficacy is also lim-
ited by disease location, once ileal dis-
ease has a faster and more complete re-
sponse to treatment when compared to
more diffuse disease or colonic or peri-
anal disease15,33. Another limitation is
the early relapse that occurs in 60 to
70% of patients in one year67. Despite
the benefit of early remission induc-
tion on active CD, further data are
necessary for better evaluation of en-
teral diet therapy on CD complicated
by fistula and stenosis.
In children with CD, disease activ-
ity is the most important cause of
growth failure. In this group, the need
to maintain remission of active disease
for longer periods has brought forward
two different nutritional strategies: ex-
clusive EN therapy for 30 days plus cy-
clic refeeding, and daytime free diet
plus night time EN supplement (naso-
gastric route, 4-5 times per week)33. The
use of enteral diet enriched with trans-
forming growth factor beta 2 (TGF-b2)
has also shown benefits such as histo-
logical improvement and reduction of
IL-1, IL-8 and IFN-g production by the
mucosa21.
Due to the undesirable side effects
of steroid therapy on normal growth,
EN may be more appropriate in chil-
dren and teenagers, even though pri-
mary NT is not as effective as drug
therapy.
In general, EN should be preferred
to TPN in NT. As primary therapy to
active CD, data suggest that EN has
equal efficacy compared to TPN, but
it is less effective compared to
corticosteroids. EN plays an important
role in selected cases unresponsive to
usual treatment and in children / teen-
agers.
Although remission rates of el-
emental and polymeric diets are simi-
lar, it is known that polymeric diets are
more efficient concerning the improve-
ment of nutritional state. The associa-
tion between lower remission rates and
LCT intake still needs confirmation47.
Finally, EN is not efficient as pri-
mary therapy for clinical remission of
ulcerative colitis patients28,59.
SPECIFIC NUTRIENTS IN NT
In IBD, some factors may lead to
intestinal epithelial cells damage, and
some nutrients are important to main-
tain intestinal structure and function
(Table 2). Treatment of gastrointestinal
diseases with specific nutrients is a
new therapeutic modality based on
their pharmacological properties. This
concept is called pharmacological nu-
trition.
Thus, a rational plan must include
nutrients to provide calories, to induce
low antigenic stimuli, to regulate in-
flammatory and immunologic re-
sponses and to stimulate mucosal tro-
phism41,75.
Glutamine (GLN) is the most com-
mon aminoacid in mammals’ blood. It
is considered the main oxidative fuel
of epithelial cells, especially jejunal
enterocytes80. Although GLN is a non-
essential aminoacid, experimental and
clinical data suggest that it may be-
come conditionally essential in cata-
bolic states9,80. Since conventional
TPN solutions and enteral nutrition do
not provide adequate amount of GLN
to a catabolic patient, GLN supple-
mentation may improve structural in-
tegrity, function and intestinal recov-
ery in catabolic conditions associated
to radiation therapy, chemotherapy, in-
flammation, trauma and sepsis7,48.
However, the limited data concern-
ing the use of GLN suggest that there
is not clear evidence of its therapeutic
role in IBD3,14,24,78,88.
Short chain fatty acids (SCFA) are
organic fatty acids derived from the
bacterial degradation of dietary carbo-
hydrate5,12. More than 90% of the
SCFA found in humans are acetate, pro-
pionate and butyrate.
Nowadays it is a consensus that
SCFA have an important role in normal
colon physiology, once they are the
main energy source to the colonocyte.
They also stimulate cellular prolifera-
tion, visceral blood flow and enhance
sodium and water absorption from the
intestinal lumen. Butyrate is the main
oxidative fuel of colonocytes, repre-
senting 70% of the total energy con-
sumption10,43,74.
Besides this, data concerning SCFA
role in the physiopathology and man-
agement of ulcerative colitis (UC) are
contradictory69,43,74. The association be-
tween SCFA and “pouchitis” after re-
storative proctocolectomy (RPC) has
also been a matter of discussion, in
what the occurrence of fecal stasis could
lead to important changes in luminal
environment, like bacterial overgrowth,
bile acids action and SCFA altera-
tions5,71.
It has also been discussed if
pouchitis and UC could have a com-
mon etiology, UC recurrence being
proposed as a cause of pouchitis64,84.
However, the association between
SCFA and pouchitis deserves new con-
trolled trials for better comprehension.
Recently, the potential role of lipid
emulsions supplemented with omega-
3 fatty acids (n-3 FA) has received
great attention regarding nutritional
therapy in several conditions1,62. It is
well known that exogenous provision
of fish oil-derived FA promotes a fast
enhancement of n-3 FA plasmatic con-
centrations, establishing an extracellu-
lar enzymatic competition between n-
3 FA and arachidonic acid (AA), de-
creasing pro-inflammatory mediators
synthesized from AA and increasing
the concentration of less potent in-
flammatory mediators synthesized
from n-3 FA1,36 (Fig. 1).
In IBD patients, treatment with oral
or parenteral n-3 FA has had favourable
results in clinical trials and experimen-
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tal studies, decreasing symptoms, cor-
ticosteroid needs, and promoting co-
lonic histological and endoscopic im-
provement2,27,40,58. These effects are at-
tributed to alteration in the inflamma-
tory mediator profile63.
Literature data suggest that
parenteral n-3 FA leads to more effec-
tive and earlier benefits when com-
pared to the enteral route. It is believed
that fast changes in plasmatic and
membrane FA composition lead to al-
terations on lipidic mediators synthe-
sis and earlier clinical results8,37,46.
Otherwise, parenteral utilization of
n-3 FA still requires evaluation of
other factors such as triglyceride chain
dimension, treatment duration, n-3/n-
6 ratio and association to other im-
mune modulator nutrients. Further as-
sessment of efficacy, costs, risks and
side effects will bring new lights into
the treatment of IBD with immune
modulatory therapies56.
CONCLUSIONS
Malnutrition in IBD patients is fre-
quent, multifactorial and has many
deleterious consequences. Its manage-
ment requires identification of nutri-
tional deficits in order to choose the
best nutritional therapy in each situa-
tion.
TPN may correct nutritional defi-
cits, maintain nutritional status and
serve as primary therapy in patients
with active CD. However, due to the
associated high costs and complication
rates, EN is the route of choice for nu-
tritional therapy. Several studies at-
tested the efficacy of enteral formula-
tions to control disease activity in CD
patients.
Clinical and experimental use of
trophic nutrients as glutamine, SCFA,
and immune modulator nutrients as n-
3 FA brought up new perspectives. De-
spite positive preliminary results, fur-
ther prospective and controlled trials
are necessary to establish their role in
IBD management.
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Figure 1 - Eicosanoids derived from eycosapentanoic (EPA) and arachidonic (AA) acids.
RESUMO RHCFAP/3091
CAMPOS FG e col. - Doenças inflama-
tórias intestinais. Princípios da te-
rapia nutricional. Rev. Hosp. Clín.
Fac. Med. S. Paulo 57(4):187-198,
2002.
As doenças inflamatórias intestinais
- retocolite ulcerativa inespecífica e
doença de Crohn - são afecções infla-
matórias gastrointestinais crônicas de
causa ainda desconhecida. Caracteri-
zam-se por diarréia crônica, mal-
absorção, síndrome do intestino curto,
disfunção da barreira mucosa e proces-
so inflamatório intestinal, fatores que
determinam deficiências nutricionais e
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funcionais que ressaltam a importância
da terapia nutricional em seu tratamen-
to. As diversas formas de terapia
nutricional visam corrigir os distúrbios
nutricionais e modular à resposta infla-
matória, podendo, desta forma, influir
na atividade da doença. A nutrição
parenteral total tem sido usada para cor-
rigir os distúrbios nutricionais e propor-
cionar repouso intestinal na doença ati-
va. Seu uso deve ser reservado a paci-
entes que não podem tolerar a nutrição
enteral. A nutrição enteral é efetiva em
induzir remissão clínica da doença em
adultos e promover crescimento em cri-
anças. Devido à baixa incidência de
complicações e menor custo, a nutrição
enteral deve ser opção preferencial à
nutrição parenteral total quando possí-
vel. Ambas apresentam igual efetividade
na terapia primária na remissão da Do-
ença de Crohn ativa. Embora a terapia
nutricional possa melhorar a evolução
de muitos pacientes, é necessária uma
seleção criteriosa devido a seus custos
e complicações, especialmente naque-
les que requerem nutrição parenteral
total. Recentes pesquisas têm se dedi-
cado ao uso de nutrientes como agen-
tes terapêuticos primários. A imuno-
nutrição com ácidos graxos ômega-3 se
constitui numa importante alternativa
terapêutica no manuseio das doenças
inflamatórias intestinais, modulando o
processo inflamatório e modificando o
perfil de produção de eicosanóides. En-
tretanto, a real eficácia deste e outros
nutrientes (glutamina, ácidos graxos de
cadeia curta) ainda necessitam de no-
vas avaliações por estudos prospec-
tivos, controlados e randomizados.
DESCRITORES: Doenças infla-
matórias intestinais. Terapia
nutricional. Nutrição parenteral to-
tal. Nutrição enteral.
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